Xconomy |
Novo And Lilly Head For Diabetes Pricing Battle
Seeking Alpha Novo Nordisk (NYSE:NVO) needs its once-weekly GLP1 agonist semaglutide to be a smash hit, and a head-to-head win against Lilly's (NYSE:LLY) rival product Trulicity suggests that it could be. FDA approval of semaglutide - which has a PDUFA date of ... Novo Nordisk's new semaglutide trounces Lilly's scrappy Trulicity in diabetes trial Novo Nordisk Diabetes Drug Beats Lilly's Trulicity in Head-to-Head Test Novo Nordisk's New Type 2 Diabetes Drug Outperforms Eli Lilly's |
from diabetes - Google News
Social Plugin